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Introduction
• In non-Hodgkin’s lymphoma the findings of hypercalcemia as an initial
presentation is extremely rare (<3% of cases). Here we report a 67year-old man who presented with ST changes secondary to
hypercalcemia in the setting of B-cell lymphoma.

Case Presentation
• A 67-year-old Caucasian male was transferred from outside hospital
for suspected ST elevated myocardial infarction (STEMI). He reported
chest discomfort and shortness of breath at presentation. Patient’s
past medical history included coronary artery disease status post
stents 2 years ago, hypertension, and hyperlipidemia.
• Associated symptoms include 3 week history of generalized
weakness, confusion, decreased appetite, 15 lbs unintentional weight
loss.
• Physical exam was significant for dry mucosal membranes and poor
skin turgor. Cardiovascular exam was normal, and no
lymphadenopathy or organomegaly was palpated.

Case Presentation (Cont.)
• In regards to transaminitis and hypoalbuminemia on liver function tests, abdominal
ultrasound was performed and unexpectedly showed innumerable hepatic masses
most consistent with metastatic.
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• Tumor marker including alpha fetoprotein (AFP), carcinoembryonic antigen (CEA),
and prostate specific antigen (PSA) were within normal limits.
• CT of abdomen and pelvis revealed no new findings other than the known hepatic
lesions. No bowel abnormalities were found that would point towards colorectal
cancer.
• CT of chest was negative for findings significant for lung cancer.
• Finally, core needle biopsy of liver mass was performed which successfully diagnosed
aggressive diffuse large B-cell lymphoma (DLBCL) of germinal center subtype.
• Following stabilization, patient was discharged to follow-up as outpatient for
aggressive chemotherapy with R-CHOP.

Investigations
.

Laboratory Studies
Relevant Labs

Values

Normal

• Vitals were within normal limits.

Albumin corrected Ca 16.0

8.5-10.1 mg/dL

PTH

6.7

10.0-66.0 pg/ml

• EKG showed ST elevation in inferior leads with ST depression in
lateral leads. Patient was given aspirin 325mg and started on IV
heparin drip however this was discontinued by Cardiology as it was
deemed to be chronic ST changes. Additionally, serial troponins-I
were also negative.

PTHrP

<2.0

<2.0 pmol/L

1,25-(OH)2 Vit D

238.5

19.9-79.3 pg/mL

25-(OH) Vit D

51

30-100 ng/mL

SPEP & Immunofix

No monoclonal pro

NA

TSH

3.320

0.358-3.740 uIU/mL

Alpha Fetoprotein

2.5

0.5-8.0 ng/mL

Carcinoembryonic Ag

1.8

0.0-3.0 ng/mL

Prostate Specific Ag

0.150

0.0-4.0 ng/mL

• Incidentally, on initial laboratory corrected hypercalcemia was noted
(16.0 mg/dL).

Imaging Studies

Discussion & Conclusion
• This patient presented with 1,25-dihydroxyvitamin D mediated
hypercalcemia in the setting of DLBCL.

• On further evaluation parathyroid hormone (PTH) was appropriately
suppressed (6.7 pg/mL) ruling out primary hyperparathyroidism.

• Vitamin D-mediated hypercalcemia only accounts for 1-2% of
lymphoma and leukemia cases.

• To investigate this non-PTH mediated hypercalcemia, parathyroid
hormone related peptide (PTHrP), 25-hydroxyvitamin D, and 1,25dihydroxyvitamin D levels were sent. Both PTHrP and 25hydroxyvitamin D were normal, however, 1,25-dihydroxyvitamin D
was markedly elevated (238.5 pg/mL).

• In hypercalcemia of underdetermined origin, hematological
malignancies should be considered a possibility.
• Imaging for underlying organ involvement and bone marrow
biopsy/aspirate should be performed.
A. Abdominal ultrasound:
innumerable hepatic masses

• Other relevant testing included negative serum protein
electrophoresis and skeletal survey which was unrevealing of any
lytic lesions ruling out multiple myeloma.
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B. CT Abdomen and Pelvis:
hepatic hypodensities
consistent with metastatic
disease
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